These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 36435391)

  • 1. Nanomedicine-based immunotherapy for Alzheimer's disease.
    Hoque M; Samanta A; Alam SSM; Zughaibi TA; Kamal MA; Tabrez S
    Neurosci Biobehav Rev; 2023 Jan; 144():104973. PubMed ID: 36435391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advancements in Strategies for Abnormal Protein Clearance in Alzheimer's Disease.
    Gong B; Ji W; Chen X; Li P; Cheng W; Zhao Y; He B; Zhuang J; Gao J; Yin Y
    Mini Rev Med Chem; 2022; 22(17):2260-2270. PubMed ID: 35156576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Progress Towards Vaccines and Antibody-based Therapies Against Alzheimer's Disease.
    Ji W; Gong B; Jin H; Chen X; Li P; Cheng W; Zhao Y; He B; Zhuang J; Gao J; Yin Y
    Mini Rev Med Chem; 2021; 21(19):3062-3072. PubMed ID: 34353254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Insights of Nanocarrier-Mediated Gene Therapeutics to Treat Potential Impairment of Amyloid Beta Protein and Tau Protein in Alzheimer's Disease.
    Jain U; Johari S; Srivastava P
    Mol Neurobiol; 2024 Apr; 61(4):1969-1989. PubMed ID: 37831361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of tau protein in Alzheimer's disease: The prime pathological player.
    Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
    Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease.
    Wu XL; Piña-Crespo J; Zhang YW; Chen XC; Xu HX
    Chin Med J (Engl); 2017 Dec; 130(24):2978-2990. PubMed ID: 29237931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer's Disease.
    Mashal Y; Abdelhady H; Iyer AK
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond.
    Song C; Shi J; Zhang P; Zhang Y; Xu J; Zhao L; Zhang R; Wang H; Chen H
    Transl Neurodegener; 2022 Mar; 11(1):18. PubMed ID: 35300725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
    Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
    Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural polyphenol: Their pathogenesis-targeting therapeutic potential in Alzheimer's disease.
    Niu C; Dong M; Niu Y
    Eur J Med Chem; 2024 Apr; 269():116359. PubMed ID: 38537514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
    Hurtado DE; Molina-Porcel L; Iba M; Aboagye AK; Paul SM; Trojanowski JQ; Lee VM
    Am J Pathol; 2010 Oct; 177(4):1977-88. PubMed ID: 20802182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment.
    Li S; Qu L; Wang X; Kong L
    Pharmacol Ther; 2022 Mar; 231():107979. PubMed ID: 34480965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
    Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
    Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities.
    Tran HT; LaFerla FM; Holtzman DM; Brody DL
    J Neurosci; 2011 Jun; 31(26):9513-25. PubMed ID: 21715616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofibrillary Tangles of Aβx-40 in Alzheimer's Disease Brains.
    Lacosta AM; Insua D; Badi H; Pesini P; Sarasa M
    J Alzheimers Dis; 2017; 58(3):661-667. PubMed ID: 28453491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The zinc dyshomeostasis hypothesis of Alzheimer's disease.
    Craddock TJ; Tuszynski JA; Chopra D; Casey N; Goldstein LE; Hameroff SR; Tanzi RE
    PLoS One; 2012; 7(3):e33552. PubMed ID: 22457776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
    Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
    J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.